Pendal Group’s SpringWorks Therapeutics SWTX Stock Holding History

Pendal Group’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,354	Closed	-$828K	–	568
2021 Q4	$828K	Buy	+13,354	New	+$884K	0.01%	363

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pendal Group's SWTX Position: Q1 2022 in Review

Pendal Group sold out of SpringWorks Therapeutics (SWTX) in Q1 2022, closing a stake of 13,354 shares — an estimated $828K sold.

Pendal Group first reported a position in SWTX in Q4 2021 and held it in 1 quarter. The position peaked at $828K in Q4 2021. 137 funds tracked by Wall St. Rank hold SWTX as of Q1 2022.

Pendal Group reported no remaining SpringWorks Therapeutics position as of Q1 2022 after selling out during the quarter.
Pendal Group sold 13,354 SpringWorks Therapeutics shares in Q1 2022, an estimated $828K.
Pendal Group first reported a position in SpringWorks Therapeutics in Q4 2021 and held it in 1 quarter.
Pendal Group's SpringWorks Therapeutics position peaked at $828K in Q4 2021.
137 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2022.

Based on Pendal Group's 13F filing for Q1 2022, filed 25 Apr 2022.